Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Withdrawn Phase 2 Interventional

Immune Ablation and Stem Cell Support for Crohn's Disease

NCT00179842
View directory record Official record
Conditions
Crohn Disease
Interventions
Stem Cell Transplant
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 23, 2026, 10:28 AM EDT
Terminated Phase 2 Interventional Results available

A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

NCT04556383
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
GB004, Placebo
Drug
Lead sponsor
GB004, Inc.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Encinitas, California • Lancaster, California • Baton Rouge, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 23, 2026, 10:28 AM EDT
Recruiting Phase 2 Interventional

Autologous Stem Cell Transplant for Crohn's Disease

NCT03219359
View directory record Official record
Conditions
Crohn Disease
Interventions
Autologous stem cell transplant, Cyclophosphamide, Thymoglobulin, Methylprednisolone, Vedolizumab
Procedure · Drug
Lead sponsor
Aaron Etra
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 10:28 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis

NCT03259659
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 23, 2026, 10:28 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02163759
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Lakewood, Colorado • Maitland, Florida • Naples, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 23, 2026, 10:28 AM EDT
Recruiting Not applicable Interventional

Transauricular Neurostimulation for Abdominal Pain Due to DGBI

NCT07798180
View directory record Official record
Conditions
Abdominal Pain (AP), Disorders of Gut-brain Interaction
Interventions
Transcutaneous auricular neurostimulation
Device
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 10:28 AM EDT
Terminated Phase 2 Interventional

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

NCT06637631
View directory record Official record
Conditions
Crohn's Disease
Interventions
SAR441566, SAR441566 matching Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 10:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

NCT01802073
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Oral Vancomycin
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 23, 2026, 10:28 AM EDT
Completed Not applicable Interventional Results available

The Role of Fiber in the Prevention and Treatment of Fecal Incontinence

NCT04806386
View directory record Official record
Conditions
Fecal Incontinence, Irritable Bowel Syndrome With Diarrhea
Interventions
Psyllium
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 10:28 AM EDT
Recruiting Phase 2 Interventional

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT07223424
View directory record Official record
Conditions
Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular Carcinoma, Ulcerative Colitis, Esophageal Cancer, Squamous Cell Carcinoma, Gastric/GEJ, Cervical Cancer, Gastro-Esophageal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
nivolumab, pembrolizumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 23, 2026, 10:28 AM EDT
Completed Phase 2 Interventional

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

NCT04857112
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose MT-1303, High Dose MT-1303, Placebo, MT-1303
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Chandler, Arizona • Los Angeles, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 23, 2026, 10:28 AM EDT
Recruiting Phase 4 Interventional

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

NCT04314375
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose Budesonide, High Dose Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Garden Grove, California • Indianapolis, Indiana • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 23, 2026, 10:28 AM EDT
Completed Not applicable Interventional

Audio-recorded Gut-Hypnotherapy for Sleep and Pain in Pediatric Abdominal Pain Disorders

NCT07216092
View directory record Official record
Conditions
Irritable Bowel Syndrome, Disorders of Gut-brain Interaction
Interventions
Gut-directed Hypnotherapy
Other
Lead sponsor
Children's Hospital at Montefiore
Other
Eligibility
8 Years to 18 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Mahwah, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 10:28 AM EDT
Terminated No phase listed Observational

Use of PET-CT in the Management of Crohn's Disease

NCT01182467
View directory record Official record
Conditions
Crohn's Disease
Interventions
PET-CT scan
Radiation
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 23, 2026, 10:28 AM EDT
Completed Phase 2 Interventional

A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT04129619
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
ORP-101, Placebo
Drug
Lead sponsor
OrphoMed, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
74
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 23, 2026, 10:28 AM EDT
Recruiting Phase 4 Interventional

Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

NCT06997965
View directory record Official record
Conditions
Crohn Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Orlando, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 10:28 AM EDT
Not listed No phase listed Observational

Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis

NCT06311123
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic Moderate
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 23, 2026, 10:28 AM EDT
Completed Phase 1 Interventional

A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.

NCT01659762
View directory record Official record
Conditions
Crohn's Disease
Interventions
autologous mesenchymal stromal cell
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 23, 2026, 10:28 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Familial Inflammatory Bowel Disease Early Risk

NCT07791862
View directory record Official record
Conditions
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn Disease (CD), Ulcerative Colitis (UC)
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
0 Years to 55 Years
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2036
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 10:28 AM EDT
Completed No phase listed Observational

SIBO, Immune Activation, and FGIDs in Children

NCT02872961
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth, Irritable Bowel Syndrome, Functional Dyspepsia, Functional Abdominal Pain
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
4 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 23, 2026, 10:28 AM EDT
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 23, 2026, 10:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

NCT02162862
View directory record Official record
Conditions
Sleep Disturbance, Fatigue, Inflammatory Bowel Disease
Interventions
Behavioral Counseling, bupropion-SR
Behavioral · Drug
Lead sponsor
Eva Szigethy
Other
Eligibility
15 Years to 30 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 23, 2026, 10:28 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT01880424
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Placebo, Linaclotide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
52
States / cities
Huntsville, Alabama • North Little Rock, Arkansas • Phoenix, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 23, 2026, 10:28 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05668013
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
18
States / cities
San Diego, California • Kissimmee, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 10:28 AM EDT